Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. Beasley, R. W, Donohue, J. F, Mehta, R., Nelson, H. S, Clay, M., Moton, A., Kim, H., & Hederer, B. M BMJ Open, 5(2):e006131, February, 2015. Number: 2![Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3%) vs 6 events (0.8%); difference −0.52 percentage point; 95% CI −1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0% in the QMF149 group and 73.4% in the MF group). Serious adverse events occurred in 4% and 5.8% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.
@article{beasley_effect_2015,
title = {Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial},
volume = {5},
url = {http://bmjopen.bmj.com/content/5/2/e006131.abstract},
doi = {10.1136/bmjopen-2014-006131},
abstract = {Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3\%) vs 6 events (0.8\%); difference −0.52 percentage point; 95\% CI −1.25 to 0.21, p=0.160, HR=0.31; 95\% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95\% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0\% in the QMF149 group and 73.4\% in the MF group). Serious adverse events occurred in 4\% and 5.8\% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.},
number = {2},
journal = {BMJ Open},
author = {Beasley, Richard W and Donohue, James F and Mehta, Rajendra and Nelson, Harold S and Clay, Michelle and Moton, Allen and Kim, Han-Joo and Hederer, Bettina M},
month = feb,
year = {2015},
note = {Number: 2},
pages = {e006131},
}
Downloads: 0
{"_id":"mvuGWtMzMMdiBixBT","bibbaseid":"beasley-donohue-mehta-nelson-clay-moton-kim-hederer-effectofoncedailyindacaterolmaleatemometasonefuroateonexacerbationriskinadolescentandadultasthmaadoubleblindrandomisedcontrolledtrial-2015","author_short":["Beasley, R. W","Donohue, J. F","Mehta, R.","Nelson, H. S","Clay, M.","Moton, A.","Kim, H.","Hederer, B. M"],"bibdata":{"bibtype":"article","type":"article","title":"Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial","volume":"5","url":"http://bmjopen.bmj.com/content/5/2/e006131.abstract","doi":"10.1136/bmjopen-2014-006131","abstract":"Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3%) vs 6 events (0.8%); difference −0.52 percentage point; 95% CI −1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0% in the QMF149 group and 73.4% in the MF group). Serious adverse events occurred in 4% and 5.8% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.","number":"2","journal":"BMJ Open","author":[{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard","W"],"suffixes":[]},{"propositions":[],"lastnames":["Donohue"],"firstnames":["James","F"],"suffixes":[]},{"propositions":[],"lastnames":["Mehta"],"firstnames":["Rajendra"],"suffixes":[]},{"propositions":[],"lastnames":["Nelson"],"firstnames":["Harold","S"],"suffixes":[]},{"propositions":[],"lastnames":["Clay"],"firstnames":["Michelle"],"suffixes":[]},{"propositions":[],"lastnames":["Moton"],"firstnames":["Allen"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Han-Joo"],"suffixes":[]},{"propositions":[],"lastnames":["Hederer"],"firstnames":["Bettina","M"],"suffixes":[]}],"month":"February","year":"2015","note":"Number: 2","pages":"e006131","bibtex":"@article{beasley_effect_2015,\n\ttitle = {Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial},\n\tvolume = {5},\n\turl = {http://bmjopen.bmj.com/content/5/2/e006131.abstract},\n\tdoi = {10.1136/bmjopen-2014-006131},\n\tabstract = {Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3\\%) vs 6 events (0.8\\%); difference −0.52 percentage point; 95\\% CI −1.25 to 0.21, p=0.160, HR=0.31; 95\\% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95\\% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0\\% in the QMF149 group and 73.4\\% in the MF group). Serious adverse events occurred in 4\\% and 5.8\\% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.},\n\tnumber = {2},\n\tjournal = {BMJ Open},\n\tauthor = {Beasley, Richard W and Donohue, James F and Mehta, Rajendra and Nelson, Harold S and Clay, Michelle and Moton, Allen and Kim, Han-Joo and Hederer, Bettina M},\n\tmonth = feb,\n\tyear = {2015},\n\tnote = {Number: 2},\n\tpages = {e006131},\n}\n\n","author_short":["Beasley, R. W","Donohue, J. F","Mehta, R.","Nelson, H. S","Clay, M.","Moton, A.","Kim, H.","Hederer, B. M"],"key":"beasley_effect_2015","id":"beasley_effect_2015","bibbaseid":"beasley-donohue-mehta-nelson-clay-moton-kim-hederer-effectofoncedailyindacaterolmaleatemometasonefuroateonexacerbationriskinadolescentandadultasthmaadoubleblindrandomisedcontrolledtrial-2015","role":"author","urls":{"Paper":"http://bmjopen.bmj.com/content/5/2/e006131.abstract"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/ADSE32SF/items?key=hSjrOPQRRHHWY81SKs6CEz45&format=bibtex&limit=100","dataSources":["gGpK74fBRMaZuy46n","JuxD99YMQsfjjQh2b","477QN6SvdKQPLJFBK","FMXzLAchXDwwwksnk"],"keywords":[],"search_terms":["effect","once","daily","indacaterol","maleate","mometasone","furoate","exacerbation","risk","adolescent","adult","asthma","double","blind","randomised","controlled","trial","beasley","donohue","mehta","nelson","clay","moton","kim","hederer"],"title":"Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial","year":2015}